Luc Ceugnart
Research Subjects
Luc Ceugnart has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- S Taïeb
Service imagerie médicale, centre Oscar-Lambret, 3, rue Frédéric-Combenale, 59000 Lille, France
9 shared publications - C. Chaveron
Lille – FRANCE
6 shared publications F. Bachelle
6 shared publications- Sophie Taieb
Department of Radiology, Centre Oscar Lambret, Lille, France
5 shared publications N. Rocourt
4 shared publications- Eric Leblanc
Centre de lutte contre le cancer Oscar Lambret
3 shared publications
Latest Publications
- Open Access
Diagnostic Value of the Texture Analysis Parameters of Retroperitoneal Residual Masses on Computed Tomographic Scan after Chemotherapy in Non-Seminomatous Germ Cell Tumors
After chemotherapy, patients with non-seminomatous germ cell tumors (NSGCTs) with residual masses >1 cm on computed tomography (CT) undergo surgery. However, in approximately 50% of cases, these masses only consist of necrosis/fibrosis. We aimed to develop a radiomics score to predict the malignant character of residual masses to avoid surgical overtreatment. Patients with NSGCTs who underwent surgery for residual masses between September 2007 and July 2020 were retrospectively identified from a unicenter database. Residual masses were delineated on post-chemotherapy contrast-enhanced CT scans. Tumor textures were obtained using the free software LifeX. We constructed a radiomics score using a penalized logistic regression model in a training dataset, and evaluated its performance on a test dataset. We included 76 patients, with 149 residual masses; 97 masses were malignant (65%). In the training dataset (n = 99 residual masses), the best model (ELASTIC-NET) led to a radiomics score based on eight texture features. In the test dataset, the area under the curve (AUC), sensibility, and specificity of this model were respectively estimated at 0.82 (95%CI, 0.69–0.95), 90.6% (75.0–98.0), and 61.1% (35.7–82.7). Our radiomics score may help in the prediction of the malignant nature of residual post-chemotherapy masses in NSGCTs before surgery, and thus limit overtreatment. However, these results are insufficient to simply select patients for surgery.
Open AccessDiagnostic Value of the Texture Analysis Parameters of Retroperitoneal Residual Masses on Computed Tomographic Scan after Chemotherapy in Non-Seminomatous Germ Cell Tumors
After chemotherapy, patients with non-seminomatous germ cell tumors (NSGCTs) with residual masses >1 cm on computed tomography (CT) undergo surgery. However, in approximately 50% of cases, these masses only consist of necrosis/fibrosis. We aimed to develop a radiomics score to predict the malignant character of residual masses to avoid surgical overtreatment. Patients with NSGCTs who underwent surgery for residual masses between September 2007 and July 2020 were retrospectively identified from a unicenter database. Residual masses were delineated on post-chemotherapy contrast-enhanced CT scans. Tumor textures were obtained using the free software LifeX. We constructed a radiomics score using a penalized logistic regression model in a training dataset, and evaluated its performance on a test dataset. We included 76 patients, with 149 residual masses; 97 masses were malignant (65%). In the training dataset (n = 99 residual masses), the best model (ELASTIC-NET) led to a radiomics score based on eight texture features. In the test dataset, the area under the curve (AUC), sensibility, and specificity of this model were respectively estimated at 0.82 (95%CI, 0.69–0.95), 90.6% (75.0–98.0), and 61.1% (35.7–82.7). Our radiomics score may help in the prediction of the malignant nature of residual post-chemotherapy masses in NSGCTs before surgery, and thus limit overtreatment. However, these results are insufficient to simply select patients for surgery.
- 20 May 2022
- Published by Elsevier in Bulletin du Cancer
- Vol. 109 (7-8) , 768-779
Seconde lecture en dépistage organisé du cancer du sein. États des lieux et perspectives d’évolution
- 20 May 2022
- Published by Elsevier in Bulletin du Cancer
- Vol. 109 (7-8) , 768-779
Seconde lecture en dépistage organisé du cancer du sein. États des lieux et perspectives d’évolution
- 30 April 2019
- Published by Elsevier in Bulletin du Cancer
- Vol. 106 (7-8) , 684-692
Dépistage organisé du cancer du sein : point de vue du radiologue
- 30 April 2019
- Published by Elsevier in Bulletin du Cancer
- Vol. 106 (7-8) , 684-692
Dépistage organisé du cancer du sein : point de vue du radiologue
- 1 April 2014
- Published by Elsevier in Journal de Radiologie Diagnostique et Interventionnelle
- Vol. 95 (4) , 357-362
Dépistage organisé du cancer du sein : des éléments de réponse aux controverses récurrentes
- 1 April 2014
- Published by Elsevier in Journal de Radiologie Diagnostique et Interventionnelle
- Vol. 95 (4) , 357-362
Dépistage organisé du cancer du sein : des éléments de réponse aux controverses récurrentes
- 1 September 2013
- Published by Elsevier in Journal de Radiologie Diagnostique et Interventionnelle
- Vol. 94 (9) , 873-881
Métaplasie cylindrique atypique isolée : intérêt d’une chirurgie systématique ?
- 1 September 2013
- Published by Elsevier in Journal de Radiologie Diagnostique et Interventionnelle
- Vol. 94 (9) , 873-881
Métaplasie cylindrique atypique isolée : intérêt d’une chirurgie systématique ?
- 1 September 2013
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 94 (9) , 861-869
Pure flat epithelial atypia: Is there a place for routine surgery?
- 1 September 2013
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 94 (9) , 861-869
Pure flat epithelial atypia: Is there a place for routine surgery?
- 14 June 2013
- Published by Tech Science Press in Oncologie
- Vol. 15 (6) , 343-345
Que penser des polémiques récentes sur le dépistage organisé des cancers du sein ?
- 14 June 2013
- Published by Tech Science Press in Oncologie
- Vol. 15 (6) , 343-345
Que penser des polémiques récentes sur le dépistage organisé des cancers du sein ?
- Open Access
- 30 January 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 24
Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking
To describe post-CyberKnife® imaging characteristics of liver metastases as an aid in assessing response to treatment, and a novel set of combined criteria (CC) as an alternative to response according to change in size (RECIST). Imaging data and medical records of 28 patients with 40 liver metastases treated with stereotactic body radiotherapy (SBRT) were reviewed. Tumor size, CT attenuation coefficient, and contrast enhancement of lesions were evaluated up to 2 years post SBRT. Rates of local control, progression-free survival, time to progression, and overall survival according to RECIST and CC were estimated. Complete response (CR) was 3.6% (95% CI: 0.1-18%) and 18% (95% CI: 6-37%) according to RECIST and combined criteria, respectively. Two progressive diseases and two partial responses according to RECIST were classified as CR by the combined criteria and one stable response according to RECIST was classified as progressive by CC (Stuart-Maxwell test, p = 0.012). The disease control rate was 60.7% (95% CI: 41-78%) by RECIST and 64% (95% CI: 44%-81%) by CC. Use of response criteria based on change in size alone in the interpretation of liver response to SBRT may be inadequate. We propose a simple algorithm with a combination of criteria to better assess tumor response. Further studies are needed to confirm their validity.
- 30 January 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 24
Open AccessImage-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking
To describe post-CyberKnife® imaging characteristics of liver metastases as an aid in assessing response to treatment, and a novel set of combined criteria (CC) as an alternative to response according to change in size (RECIST). Imaging data and medical records of 28 patients with 40 liver metastases treated with stereotactic body radiotherapy (SBRT) were reviewed. Tumor size, CT attenuation coefficient, and contrast enhancement of lesions were evaluated up to 2 years post SBRT. Rates of local control, progression-free survival, time to progression, and overall survival according to RECIST and CC were estimated. Complete response (CR) was 3.6% (95% CI: 0.1-18%) and 18% (95% CI: 6-37%) according to RECIST and combined criteria, respectively. Two progressive diseases and two partial responses according to RECIST were classified as CR by the combined criteria and one stable response according to RECIST was classified as progressive by CC (Stuart-Maxwell test, p = 0.012). The disease control rate was 60.7% (95% CI: 41-78%) by RECIST and 64% (95% CI: 44%-81%) by CC. Use of response criteria based on change in size alone in the interpretation of liver response to SBRT may be inadequate. We propose a simple algorithm with a combination of criteria to better assess tumor response. Further studies are needed to confirm their validity.
- 1 July 2012
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 93 (7-8) , 561-568
Clinical utility and economic viability of a 3T MRI in an anti-cancer centre: The experience of the centre Oscar Lambret
- 1 July 2012
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 93 (7-8) , 561-568
Clinical utility and economic viability of a 3T MRI in an anti-cancer centre: The experience of the centre Oscar Lambret
- 1 September 2010
- Published by Elsevier in Journal de Radiologie
- Vol. 91 (9) , 879-883
Comparaison entre le zoom numérique et l’agrandissement géométrique dans l’étude des foyers de microcalcifications en mammographie numérique
- 1 September 2010
- Published by Elsevier in Journal de Radiologie
- Vol. 91 (9) , 879-883
Comparaison entre le zoom numérique et l’agrandissement géométrique dans l’étude des foyers de microcalcifications en mammographie numérique